Evidence map›Paper›PMID 36922793›Full record

ArticleBMC cardiovascular disorders2023

Tissue and plasma proteomic profiling indicates AHSG as a potential biomarker for ascending thoracic aortic aneurysms.

Rafailia Kazamia, Anna Keravnou, Areti Moushi, Kleitos Sokratous, Kyriaki Michailidou, Kristia Yiangou, Marinos Soteriou, Stavroulla Xenophontos, Marios A Cariolou, Evy Bashiardes

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rafailia KazamiaDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Anna KeravnouDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Areti MoushiDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Kleitos SokratousOMass Therapeutics, The Schrödinger Building, Heatley Road, The Oxford Science Park, Oxford, OX4 4GE, UK.
Kyriaki MichailidouBiostatistics Unit, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Kristia YiangouDepartment of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Marinos SoteriouDepartment of Cardiology and Cardiovascular Surgery, American Medical Centre, Spyrou Kyprianou Avenue 215, 2047, Nicosia, Strovolos, Cyprus.
Stavroulla XenophontosDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Marios A CariolouDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus.
Evy BashiardesDepartment of Cardiovascular Genetics and The Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Agios Dometios, 2371, Nicosia, Cyprus. evyb@cing.ac.cy.
Cyprus Institute of Neurology and Genetics · CYAmerican Heart Institute · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThoracic Aortic Aneurysms (TAAs) develop asymptomatically and are characterized by dilatation of the aorta. This is considered a life-threatening vascular disorder due to the risk of aortic dissection and rupture. There is an urgent need to identify blood-borne biomarkers for the early detection of TAA. The goal of the present study was to identify potential protein biomarkers associated with TAAs, using proteomic analysis of aortic tissue and plasma samples.

methodsExtracted proteins from 14 aneurysmal and 12 non-aneurysmal thoracic aortic tissue specimens as well as plasma samples from six TAA patients collected pre-and postoperatively and six healthy controls (HC), were analyzed by liquid chromatography-tandem mass spectrometry. Proteomic data were further processed and following filtering criteria, one protein was selected for verification and validation in a larger cohort of patients and controls using a targeted quantitative proteomic approach and enzyme-linked immunosorbent assay, respectively.

resultsA total of 1593 and 363 differentially expressed proteins were identified in tissue and plasma samples, respectively. Pathway enrichment analysis on the differentially expressed proteins revealed a number of dysregulated molecular pathways that might be implicated in aneurysm pathology including complement and coagulation cascades, focal adhesion, and extracellular matrix receptor interaction pathways. Alpha-2-HS glycoprotein (AHSG) was selected for further verification in 36 TAA and 21 HC plasma samples using targeted quantitative proteomic approach. The results showed a significantly decreased concentration of AHSG (p = 0.0002) in the preoperative plasma samples compared with HC samples. Further analyses using a larger validation dataset revealed that AHSG protein levels were significantly lower (p = 0.03) compared with HC. Logistic regression analysis on the validation dataset revealed males, advanced age, hypertension and hyperlipidaemia as significant risk factors for TAA.

conclusionAHSG concentrations distinguish plasma samples derived from TAA patients and controls. The findings of this study suggest that AHSG may be a potential biomarker for TAA that could lead to better diagnostic capabilities.

Indexed as

alpha-2-HS-GlycoproteinAortic Aneurysm, ThoracicBiomarkersHumansMaleProteinsProteomicsAHSG protein, humanalpha-2-HS-GlycoproteinBiomarkersProteinsAHSGAortic tissueBiomarkersBlood-borneMass spectrometryPlasmaProteomicTAAThoracic aortic aneurysm

Identifiers

PMID36922793
PMCPMC10018995
OpenAlexW4327685953

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read49
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.